Verve Therapeutics to Participate in Upcoming Investor Conferences
30. Mai 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
08. Mai 2024 07:00 ET
|
Verve Therapeutics
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
07. Mai 2024 07:00 ET
|
Verve Therapeutics
VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03. Mai 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Updates on its PCSK9 Program
02. April 2024 07:00 ET
|
Verve Therapeutics
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28. März 2024 16:51 ET
|
Verve Therapeutics
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01. März 2024 16:01 ET
|
Verve Therapeutics
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27. Februar 2024 07:30 ET
|
Verve Therapeutics
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of...
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01. Februar 2024 06:30 ET
|
Verve Therapeutics
BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02. Januar 2024 06:30 ET
|
Verve Therapeutics
BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...